KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Treasury Shares (2016 - 2025)

Nektar Therapeutics has reported Treasury Shares over the past 13 years, most recently at $208100.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $208100.0 for Q4 2025, down 62.32% from a year ago — trailing twelve months through Dec 2025 was $208100.0 (down 62.32% YoY), and the annual figure for FY2025 was $208100.0, down 62.32%.
  • Treasury Shares for Q2 2025 was $3.0 million at Nektar Therapeutics, roughly flat from $3.0 million in the prior quarter.
  • Over the last five years, Treasury Shares for NKTR hit a ceiling of $9.9 million in Q4 2021 and a floor of $208100.0 in Q4 2025.
  • Median Treasury Shares over the past 4 years was $552307.0 (2024), compared with a mean of $2.5 million.
  • Peak annual rise in Treasury Shares hit 0.0% in 2025, while the deepest fall reached 0.0% in 2025.
  • Nektar Therapeutics' Treasury Shares stood at $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025.
  • The last three reported values for Treasury Shares were $208100.0 (Q4 2025), $552307.0 (Q2 2025), and $552307.0 (Q1 2025) per Business Quant data.